Proteomic analysis of a meningococcal outer membrane vesicle vaccine prepared from the group B strain NZ98/254.

Journal article

In the absence of a suitable carbohydrate-based vaccine, outer membrane vesicle (OMV) vaccines have been used to disrupt outbreaks of serogroup B meningococcal disease for more than 20 years. Proteomic technology provides physical methods with the potential to assess the composition and consistency of these complex vaccines. 2-DE, combined with MS, were used to generate a proteome map of an OMV vaccine, developed to disrupt a long-running outbreak of group B disease in New Zealand. Seventy fo...

Expand abstract

Authors: Vipond, C; Suker, J; Jones, C; Tang, C; Feavers, I

• Journal: Proteomics
• Volume: 6
• Issue: 11
• Pages: 3400-3413
• Publication date: 2006-06-01
• DOI: 10.1002/pmic.200500821
• EISSN: 1615-9861
• ISSN: 1615-9853
• Language: English
• Keywords: Bacterial Outer Membrane Proteins; Proteomics; Humans; Antigens, Bacterial; Neisseria meningitidis, Serogroup B; Mass Spectrometry; Electrophoresis, Gel, Two-Dimensional; Meningococcal Vaccines